Bausch Health Companies Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Bausch Health Companies Inc. (BHC) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-05-09
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-03-31 was $0.00.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was -$400.00K, a 105.19% decline year-over-year.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was -$1.00M, a 105.59% decline year-over-year.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-12-31 was $35.10M.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $56.80M, a 232.16% increase from fiscal 2014.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $17.10M, a 29.34% decline from fiscal 2013.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $24.20M, a 93.60% increase from fiscal 2012.
- Bausch Health Companies Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $12.50M, a 52.89% decline from fiscal 2011.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | |||||||
| 2016-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$1.40M 10-Q · filed 2016-08-09 | $33.70M derived: sum of 3 quarters · filed 2017-05-09 | $29.80M derived: sum of 4 quarters · filed 2017-05-09 | ||||
| 2016-03-31 | -$1.00M 10-Q · filed 2017-05-09 | -$1.40M 10-Q · filed 2016-06-07 | $34.10M derived: sum of 2 quarters · filed 2017-05-09 | $30.20M derived: sum of 3 quarters · filed 2017-05-09 | $37.90M derived: sum of 4 quarters · filed 2017-05-09 | |||
| 2015-12-31 | $35.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $31.20M derived: sum of 2 quarters · filed 2016-04-29 | $38.90M derived: sum of 3 quarters · filed 2016-04-29 | $56.80M 10-K · filed 2016-04-29 | ||||
| 2015-09-30 | -$3.90M 10-Q · filed 2015-10-26 | $3.80M derived: sum of 2 quarters · filed 2015-10-26 | $21.70M 10-Q · filed 2015-10-26 | $21.70M derived: sum of 4 quarters · filed 2016-06-07 | ||||
| 2015-06-30 | $7.70M 10-Q · filed 2015-07-28 | $25.60M 10-Q · filed 2016-08-09 | $25.60M derived: sum of 3 quarters · filed 2016-06-07 | $41.50M derived: sum of 4 quarters · filed 2016-06-07 | ||||
| 2015-03-31 | $17.90M 10-Q · filed 2016-06-07 | $17.90M derived: sum of 2 quarters · filed 2016-06-07 | $33.80M derived: sum of 3 quarters · filed 2016-06-07 | $33.80M derived: sum of 4 quarters · filed 2016-06-07 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $15.90M derived: sum of 2 quarters · filed 2016-04-29 | $15.90M derived: sum of 3 quarters · filed 2016-04-29 | $17.10M 10-K · filed 2016-04-29 | ||||
| 2014-09-30 | $15.90M 10-Q · filed 2015-10-26 | $15.90M derived: sum of 2 quarters · filed 2015-10-26 | $17.10M 10-Q · filed 2015-10-26 | -$7.30M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-06-30 | $0.00 10-Q · filed 2015-07-28 | $1.20M 10-Q · filed 2015-07-28 | -$23.20M derived: sum of 3 quarters · filed 2016-04-29 | $9.00M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-03-31 | $1.20M 10-Q · filed 2015-04-30 | -$23.20M derived: sum of 2 quarters · filed 2016-04-29 | $9.00M derived: sum of 3 quarters · filed 2016-04-29 | $20.80M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2013-12-31 | -$24.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $7.80M derived: sum of 2 quarters · filed 2016-04-29 | $19.60M derived: sum of 3 quarters · filed 2016-04-29 | $24.20M 10-K · filed 2016-04-29 | ||||
| 2013-09-30 | $32.20M 10-Q · filed 2014-10-24 | $32.18M 10-Q · filed 2013-11-01 | $44.00M derived: sum of 2 quarters · filed 2014-10-24 | $48.60M 10-Q · filed 2014-10-24 | $48.63M 10-Q · filed 2013-11-01 | $55.26M derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-06-30 | $11.80M 10-Q · filed 2014-08-01 | $11.85M 10-Q · filed 2013-08-07 | $16.40M 10-Q · filed 2014-08-01 | $16.45M 10-Q · filed 2013-08-07 | $23.06M derived: sum of 3 quarters · filed 2015-02-25 | $25.43M derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-03-31 | $4.60M 10-Q · filed 2014-05-09 | $4.60M 10-Q · filed 2013-05-03 | $11.26M derived: sum of 2 quarters · filed 2015-02-25 | $13.63M derived: sum of 3 quarters · filed 2015-02-25 | $16.51M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2012-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $9.03M derived: sum of 2 quarters · filed 2015-02-25 | $11.91M derived: sum of 3 quarters · filed 2015-02-25 | $12.50M 10-K · filed 2015-02-25 | $12.54M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $2.37M 10-Q · filed 2013-11-01 | $5.25M derived: sum of 2 quarters · filed 2013-11-01 | $5.84M 10-Q · filed 2013-11-01 | -$1.28M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-06-30 | $2.88M 10-Q · filed 2013-08-07 | $3.48M 10-Q · filed 2013-08-07 | -$3.65M derived: sum of 3 quarters · filed 2014-02-28 | -$1.61M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-03-31 | $593.00K 10-Q · filed 2013-05-03 | -$6.53M derived: sum of 2 quarters · filed 2014-02-28 | -$4.49M derived: sum of 3 quarters · filed 2014-02-28 | $3.08M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2011-12-31 | -$7.13M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$5.08M derived: sum of 2 quarters · filed 2014-02-28 | $2.48M derived: sum of 3 quarters · filed 2014-02-28 | $26.53M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | $2.04M 10-Q · filed 2012-11-05 | $9.61M derived: sum of 2 quarters · filed 2012-11-05 | $33.66M 10-Q · filed 2012-11-05 | |||||
| 2011-06-30 | $7.57M 10-Q · filed 2012-08-03 | $31.62M 10-Q · filed 2012-08-03 | ||||||
| 2011-03-31 | $24.05M 10-Q · filed 2012-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |